PARK HA BIOLOGICAL TECH CFO Buys Big Stake at $0.18, Eyes Reverse Split‑Driven Rally

CFO Zhu Xiaoyan’s Latest Purchase Signals Confidence Amidst a Volatile Share Price

On August 3, 2026, PARK HA BIOLOGICAL TECH’s Chief Financial Officer, Zhu Xiaoyan, executed a purchase of 112,500 Class A ordinary shares at $0.18 each—a price far below the current market value of $3.22. The transaction coincides with a 1‑for‑8 reverse stock split that the company announced on August 6, which will consolidate shares but leave the market capitalization unchanged. By buying at the split‑adjusted price, Zhu effectively acquires 112,500 shares that will convert to 14,062.5 shares post‑split, still representing a sizable stake for an insider who previously held only 2,500 shares.

What Does This Mean for Investors?

The timing and size of the purchase suggest that Zhu believes the stock is undervalued, even as the share price has surged over 774 % weekly and 339 % monthly—yet it remains a year‑low of $0.32. The reverse split will boost the share price to roughly $25.60 (3.22 × 8) before the market re‑estimates its value, potentially providing a liquidity event for other shareholders. For investors, the CFO’s confidence could be a bullish signal, especially if the company’s pipeline in the consumer discretionary biotech space continues to progress. However, the negative price‑earnings ratio of –0.13 and the overall yearly decline of –90 % caution that the company may still face valuation challenges.

Zhu Xiaoyan’s Insider Activity Profile

Since her appointment as CFO, Zhu has maintained a modest but consistent holding of Class A shares, with no prior purchases or sales recorded in the public filings. Her recent buy aligns with a pattern of cautious accumulation rather than speculative trading. Unlike her peers—CEO Zhang Xiaoqiu who holds a large 381,000 Class B shares and CTO Li Xinyu with 937 shares—Zhu’s moves appear deliberate and aligned with long‑term strategy rather than short‑term gains. The fact that she bought immediately after the reverse split announcement further implies a belief that the company’s fundamentals will translate into a higher per‑share value once the split is fully processed.

Implications for the Company’s Future

The CFO’s stake increase comes at a time when PARK HA BIOLOGICAL TECH is undergoing structural changes aimed at enhancing shareholder value. The reverse split will reduce the number of shares outstanding, potentially raising the stock’s perceived stability and making it more attractive to institutional investors. If the company can sustain its rapid weekly gains and move toward profitability, the CFO’s confidence may translate into a rally in share price. Conversely, should the company struggle to convert its consumer‑discretionary biotech focus into revenue, the reverse split could expose the stock to heightened volatility. Investors should monitor subsequent SEC filings, earnings releases, and any guidance from the CFO or board to gauge whether this insider purchase is a signal of genuine conviction or a defensive hedge against impending dilution.